This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ZTS Set to Report Q2 Earnings: Here's What Investors Should Expect
by Zacks Equity Research
Zoetis heads into Q2 earnings with companion animal products and international growth in focus as U.S. competition and Librela concerns weigh.
ZTSNegative Net Change ACADPositive Net Change CRSPPositive Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down
by Zacks Equity Research
TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.
TGTXPositive Net Change RGENPositive Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs earnings
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.
OTLKPositive Net Change ACADPositive Net Change ARQTPositive Net Change HRMYPositive Net Change
biotechnology biotechs medical
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
by Ekta Bagri
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
ARQTPositive Net Change NUVBPositive Net Change TNGXPositive Net Change CATXNegative Net Change
biotechnology biotechs earnings pharmaceuticals
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?
by Ekta Bagri
LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.
LQDAPositive Net Change JNJPositive Net Change UTHRPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback
by Zacks Equity Research
Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.
MRNAPositive Net Change MRKPositive Net Change ABUSPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
by Zacks Equity Research
Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.
AGIOPositive Net Change NBIXPositive Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechnology biotechs medical
4 Value Stocks to Buy as Fed Holds Rates, Mideast Risks Rise
by Rimmi Singhi
With the Fed holding rates steady and Middle East tensions clouding market sentiment, ARW, PENN, GOOS and HRMY emerge as attractive value opportunities.
ARWPositive Net Change PENNPositive Net Change GOOSPositive Net Change HRMYPositive Net Change
biotechs consumer-discretionary medical pharmaceuticals retail tech-stocks
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
by Zacks Equity Research
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
MDGLPositive Net Change LQDAPositive Net Change KNSAPositive Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals